Skip to main content

Advertisement

Table 1 Indications and response rates of infliximab induction therapy

From: Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study

Indication of IFX therapy Number and rate of disease type Response rate after induction
Therapy-refractory CD 114 (31.4%) 83.3%
   By localization   
   Ileum 10 (8.77%)  
   Colon 29 (25.4%) 79.3%
   Ileo-colonic 46 (40.4%) 87.0%
   Ileo-colonic and small bowel 28 (24.6%) 78.6%
   Oesophagus 1 (0.9%) 1/1
Therapy-refractory and fistulizing 16 (4.4%) 93.8%
Fistulizing 195 (53.7%) 85.6%
   By localization   
   Perianal 148 (75.9%) 91.2%
   Enterocutaneous 24 (12.3%) 87.5%
   Enterovaginal 11 (5.6%) 9/11
   Other 12 (6.2%) 7/12
   Mixed 7 (3.6%) 5/7
Steroid dependent 26 (7.2%) 92.3%
   By localization   
   Ileum 3 (11.5%) 3/3
   Colon 4 (15.4%) 4/4
   Ileo-colic 19 (73.1%) 17/19
Metastatic 5 (0.1%) Na.
Other 7 (0.2%) Na.
  1. Na = not applicable